Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Spectrum to have full ownership of Zevalin after getting ex-US rights from Bayer

Executive Summary

Bayer HealthCare Pharmaceuticals AG has licensed Spectrum Pharmaceuticals Inc. (solid and hematological cancers) the ex-US marketing and sales rights to Zevalin (the antibody ibritumomab linked to the radioisotope tiuxetan), indicated for follicular B-cell non-Hodgkin’s lymphoma. The deal includes patents and existing inventory.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing (Licensing)
    • Reverse Licensing

Related Companies